Table 2a.
HT recipient vaccine response, No. (%) |
|||
---|---|---|---|
Priming dose responders | Booster responders | Non-responders | |
n = 19 | n = 64 | n = 51 | |
Age group, ya | |||
18-39 | 7 (24) | 9 (31) | 13 (45) |
40-59 | 7 (18) | 20 (53) | 11 (29) |
≥60 | 5 (8) | 34 (52) | 27 (41) |
Sexb | |||
Male | 9 (14) | 34 (52) | 22 (34) |
Female | 9 (13) | 30 (45) | 28 (42) |
Racec | |||
White | 17 (14) | 59 (49) | 44 (37) |
Non-white | 2 (16) | 5 (38) | 6 (46) |
Time since transplant, y | |||
<3 | 4 (11) | 10 (26) | 24 (63) |
3-6 | 6 (15) | 19 (46) | 16 (39) |
7-11 | 3 (15) | 13 (65) | 4 (20) |
≥12 | 6 (17) | 22 (63) | 7 (20) |
Type of regimen | |||
Includes anti-metabolite maintenance immunosuppressiond | 7 (8) | 41 (47) | 40 (45) |
Does not include anti-metabolite maintenance immunosuppression | 12 (26) | 23 (50) | 11 (24) |
Vaccine | |||
mRNA-1273 (Moderna) | 12 (19) | 29 (45) | 23 (36) |
BNT16b2 (Pfizer-BioNTech) | 7 (10) | 35 (50) | 28 (40) |
HT, Heart transplant.
Missing data for 1 participant.
Missing data for 2 participants.
Missing data for 1 participant.
Antimetabolite maintenance immunosuppressive regimens included mycophenolate mofetil, mycophenolic acid, and azathioprine.